Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML)
Autor: | Stephen A. Strickland, Michael Chiarella, Daniel H. Ryan, Robert K. Stuart, Gary J. Schiller, Matthew J. Wieduwilt, Jorge E. Cortes, Bruno C. Medeiros, Jeffrey E. Lancet, Tara L. Lin, Donna E. Hogge, Richard Stone, Arthur C. Louie, Laura F. Newell, Geoffrey L. Uy, Jonathan E. Kolitz, Dale L. Bixby, Robert J. Ryan, Scott R. Solomon, Ellen K. Ritchie |
---|---|
Rok vydání: | 2018 |
Předmět: | |
Zdroj: | Journal of Clinical Oncology. 36:7040-7040 |
ISSN: | 1527-7755 0732-183X |
Popis: | 7040Background: CPX-351, a liposomal encapsulation of cytarabine (C) and daunorubicin (D) at a synergistic ratio, is approved in the US for treatment of adults with newly diagnosed therapy-related ... |
Databáze: | OpenAIRE |
Externí odkaz: |